Cargando…
A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer
BACKGROUND: Statins inhibit HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Epidemiological and pre-clinical evidence support an association between statin use and delayed prostate cancer (PCa) progression. Here, we evaluated the effects of neoadjuvant fluvastatin treatment on...
Autores principales: | Longo, Joseph, Hamilton, Robert J., Masoomian, Mehdi, Khurram, Najia, Branchard, Emily, Mullen, Peter J., Elbaz, Mohamad, Hersey, Karen, Chadwick, Dianne, Ghai, Sangeet, Andrews, David W., Chen, Eric X., van der Kwast, Theodorus H., Fleshner, Neil E., Penn, Linda Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655503/ https://www.ncbi.nlm.nih.gov/pubmed/32203069 http://dx.doi.org/10.1038/s41391-020-0221-7 |
Ejemplares similares
-
Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer
por: Ghai, Sangeet, et al.
Publicado: (2017) -
An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer
por: Longo, Joseph, et al.
Publicado: (2019) -
Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019) -
The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012) -
Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
por: Lee, Chong-Ki, et al.
Publicado: (2013)